Lake Street starts virtual primary care provider LifeMD with a Buy

As previously reported, Lake Street analyst Brooks O’Neil initiated coverage of LifeMD (LFMD) with a Buy rating and $12 price target calling it “a leading provider of virtual primary care” that offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions. The firm, which believes the company’s platform is “both timely and scalable,” sees “big potential across the entire platform” and expects continued rapid growth, increasing margins, and a path to profitability in 2025 or 2026, the analyst tells investors.